Class information for:
Level 1: SGLT2 INHIBITOR//DAPAGLIFLOZIN//CANAGLIFLOZIN

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
9043 1193 38.4 80%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
176 3       DIABETES CARE//ENDOCRINOLOGY & METABOLISM//TYPE 2 DIABETES 58057
1167 2             GLUCAGON LIKE PEPTIDE 1//GLP 1//INCRETIN 9383
9043 1                   SGLT2 INHIBITOR//DAPAGLIFLOZIN//CANAGLIFLOZIN 1193

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 SGLT2 INHIBITOR authKW 5505560 20% 89% 241
2 DAPAGLIFLOZIN authKW 3482009 12% 92% 148
3 CANAGLIFLOZIN authKW 3086265 11% 93% 129
4 EMPAGLIFLOZIN authKW 2442906 9% 94% 102
5 SGLT2 authKW 2100850 8% 84% 98
6 SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR authKW 1736185 7% 86% 79
7 SODIUM GLUCOSE COTRANSPORTER 2 authKW 905300 3% 91% 39
8 IPRAGLIFLOZIN authKW 794182 3% 97% 32
9 URINARY GLUCOSE EXCRETION authKW 694332 2% 94% 29
10 SODIUM GLUCOSE CO TRANSPORTER 2 SGLT2 INHIBITOR authKW 691033 2% 100% 27

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Endocrinology & Metabolism 7496 31% 0% 369
2 Pharmacology & Pharmacy 2285 27% 0% 322
3 Chemistry, Medicinal 672 8% 0% 92
4 Medicine, General & Internal 563 11% 0% 137
5 Urology & Nephrology 479 7% 0% 78
6 Medicine, Research & Experimental 227 6% 0% 75
7 Physiology 101 4% 0% 50
8 Chemistry, Organic 74 5% 0% 63
9 Peripheral Vascular Diseases 46 3% 0% 31
10 Primary Health Care 39 1% 0% 8

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TIANJIN MOL DESIGN DRUG DISCOVERY 143090 2% 23% 24
2 PROD PLANNING COORDINAT 91404 0% 71% 5
3 DIABET DISCOVERY BIOL 76781 0% 100% 3
4 GLOBAL MED AFFAIRS DIABET METAB 51188 0% 100% 2
5 INVEST CLIN SAN AGUSTIN 51188 0% 100% 2
6 METAB DIS DISCOVERY BIOL 51188 0% 100% 2
7 NUCLEO AVANCADO NEFROL 51188 0% 100% 2
8 OBES ENDOCRINOL 46424 1% 13% 14
9 GLOBAL BIOMETR SCI 42342 1% 14% 12
10 GLOBAL CLIN 40479 1% 13% 12

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DIABETES OBESITY & METABOLISM 87968 7% 4% 87
2 DIABETES THERAPY 45782 2% 10% 18
3 JOURNAL OF DIABETES INVESTIGATION 8758 1% 2% 14
4 CARDIOVASCULAR DIABETOLOGY 5956 1% 1% 17
5 CLINICAL THERAPEUTICS 5925 3% 1% 34
6 DIABETES CARE 4693 4% 0% 46
7 DIABETES & VASCULAR DISEASE RESEARCH 4049 1% 2% 8
8 LANCET DIABETES & ENDOCRINOLOGY 3734 1% 2% 6
9 CURRENT MEDICAL RESEARCH AND OPINION 3554 2% 1% 25
10 POSTGRADUATE MEDICINE 3304 2% 1% 26

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 SGLT2 INHIBITOR 5505560 20% 89% 241 Search SGLT2+INHIBITOR Search SGLT2+INHIBITOR
2 DAPAGLIFLOZIN 3482009 12% 92% 148 Search DAPAGLIFLOZIN Search DAPAGLIFLOZIN
3 CANAGLIFLOZIN 3086265 11% 93% 129 Search CANAGLIFLOZIN Search CANAGLIFLOZIN
4 EMPAGLIFLOZIN 2442906 9% 94% 102 Search EMPAGLIFLOZIN Search EMPAGLIFLOZIN
5 SGLT2 2100850 8% 84% 98 Search SGLT2 Search SGLT2
6 SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR 1736185 7% 86% 79 Search SODIUM+GLUCOSE+COTRANSPORTER+2+INHIBITOR Search SODIUM+GLUCOSE+COTRANSPORTER+2+INHIBITOR
7 SODIUM GLUCOSE COTRANSPORTER 2 905300 3% 91% 39 Search SODIUM+GLUCOSE+COTRANSPORTER+2 Search SODIUM+GLUCOSE+COTRANSPORTER+2
8 IPRAGLIFLOZIN 794182 3% 97% 32 Search IPRAGLIFLOZIN Search IPRAGLIFLOZIN
9 URINARY GLUCOSE EXCRETION 694332 2% 94% 29 Search URINARY+GLUCOSE+EXCRETION Search URINARY+GLUCOSE+EXCRETION
10 SODIUM GLUCOSE CO TRANSPORTER 2 SGLT2 INHIBITOR 691033 2% 100% 27 Search SODIUM+GLUCOSE+CO+TRANSPORTER+2+SGLT2+INHIBITOR Search SODIUM+GLUCOSE+CO+TRANSPORTER+2+SGLT2+INHIBITOR

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 SCHEEN, AJ , (2015) PHARMACODYNAMICS, EFFICACY AND SAFETY OF SODIUM-GLUCOSE CO-TRANSPORTER TYPE 2 (SGLT2) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS.DRUGS. VOL. 75. ISSUE 1. P. 33 -59 129 94% 43
2 SCHEEN, AJ , (2015) SGLT2 INHIBITION: EFFICACY AND SAFETY IN TYPE 2 DIABETES TREATMENT.EXPERT OPINION ON DRUG SAFETY. VOL. 14. ISSUE 12. P. 1879 -1904 108 96% 5
3 PAFILI, K , MALTEZOS, E , PAPANAS, N , (2016) THE POTENTIAL OF SGLT2 INHIBITORS IN PHASE II CLINICAL DEVELOPMENT FOR TREATING TYPE 2 DIABETES.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 25. ISSUE 10. P. 1133 -1152 92 96% 0
4 NAUCK, MA , (2014) UPDATE ON DEVELOPMENTS WITH SGLT2 INHIBITORS IN THE MANAGEMENT OF TYPE 2 DIABETES.DRUG DESIGN DEVELOPMENT AND THERAPY. VOL. 8. ISSUE . P. 1335 -1380 68 89% 49
5 SCHEEN, AJ , (2016) SGLT2 INHIBITORS: BENEFIT/RISK BALANCE.CURRENT DIABETES REPORTS. VOL. 16. ISSUE 10. P. - 75 91% 0
6 ZACCARDI, F , WEBB, DR , HTIKE, ZZ , YOUSSEF, D , KHUNTI, K , DAVIES, MJ , (2016) EFFICACY AND SAFETY OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS IN TYPE 2 DIABETES MELLITUS: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.DIABETES OBESITY & METABOLISM. VOL. 18. ISSUE 8. P. 783 -794 50 77% 12
7 TAHRANI, AA , BARNETT, AH , BAILEY, CJ , (2013) SGLT INHIBITORS IN MANAGEMENT OF DIABETES.LANCET DIABETES & ENDOCRINOLOGY. VOL. 1. ISSUE 2. P. 140-151 64 86% 46
8 ABDUL-GHANI, MA , NORTON, L , DEFRONZO, RA , (2015) RENAL SODIUM-GLUCOSE COTRANSPORTER INHIBITION IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS.AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY. VOL. 309. ISSUE 11. P. F889 -F900 70 80% 11
9 IMPRIALOS, KP , SARAFIDIS, PA , KARAGIANNIS, AI , (2015) SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AND BLOOD PRESSURE DECREASE: A VALUABLE EFFECT OF A NOVEL ANTIDIABETIC CLASS?.JOURNAL OF HYPERTENSION. VOL. 33. ISSUE 11. P. 2185 -2197 69 87% 4
10 HASAN, FM , ALSAHLI, M , GERICH, JE , (2014) SGLT2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES.DIABETES RESEARCH AND CLINICAL PRACTICE. VOL. 104. ISSUE 3. P. 297 -322 67 75% 36

Classes with closest relation at Level 1


Rank Class id link
1 7402 SGLT1//GLUT5//SODIUM ION GLUCOSE COTRANSPORTER
2 580 DPP 4 INHIBITOR//EXENATIDE//LIRAGLUTIDE
3 1970 INSULIN GLARGINE//BIPHASIC INSULIN ASPART 30//INSULIN INITIATION
4 31620 FANCONI BICKEL SYNDROME//GLYCOGEN STORAGE DISEASE TYPE XI//FANCONI BICKEL
5 20411 ASYMPTOMATIC BACTERIURIA//99M TECHNETIUM DIMERCAPTO SUCCINIC ACID//ADHESINS ESCHERICHIA COLI
6 22680 GK RAT//INSULIN GLUCOSE CLAMP//PHOSPHORYLATIVE SYSTEM
7 25070 1 5 ANHYDROGLUCITOL//1 5 ANHYDRO D FRUCTOSE//1 5 ANHYDRO D GLUCITOL
8 25009 ANTIDIABETIC PHARMACOTHERAPY//A HEFT//ACORN CSD
9 18494 RUBOXISTAURIN//LY333531//PKC BETA II INHIBITORS
10 11181 GLUT1//GLUCOSE TRANSPORTER//GLUT3

Go to start page